RBC Capital Markets has increased its price target for United Therapeutics to $725 from $697, while reiterating an Outperform rating. This adjustment follows the company's Q3 2026 financial results, indicating a positive analyst sentiment post-earnings.
RBC Capital Markets has raised its price target for United Therapeutics (UTHR) to $725, up from $697, and maintained an 'Outperform' rating. This positive revision comes after the company's third-quarter 2026 financial results, which were reported on November 4, 2026. The analyst's updated outlook suggests a favorable view of the company's recent performance and future prospects. For traders, this indicates a potential short-term positive sentiment boost for UTHR, as analyst upgrades often lead to increased investor interest. Long-term, it reinforces the bullish case for the stock, though the actual impact will depend on broader market conditions and the company's continued execution.